SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1948 9358 "

Sökning: L773:1948 9358

  • Resultat 1-9 av 9
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Ahrén, Bo (författare)
  • Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
  • 2014
  • Ingår i: World Journal of Diabetes. - : Baishideng Publishing Group Inc.. - 1948-9358. ; 5:1, s. 40-51
  • Forskningsöversikt (refereegranskat)abstract
    • There are many advantages of combining incretin therapy [glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] with insulin therapy as a glucose-lowering strategy in type 2 diabetes. One important advantage is the complementary mode of the mechanistic action of incretin and insulin therapy. Another advantage is the reduction in risk of hypoglycemia and weight gain when adding incretin therapy to insulin. Several clinical trials have studied the addition of GLP-1 receptor agonists [exenatide BID (twice daily), lixisenatide, albiglutide] or DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, alogliptin, linagliptin) to ongoing insulin therapy or adding insulin to ongoing therapy with a GLP-1 receptor agonist (liraglutide). These studies show improved glycemia in the presence of limited risk for hypoglycemia and weight gain with the combination of incretin therapy with insulin. This article reviews the background and clinical studies on this combination.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  • Naidoo, Poobalan, et al. (författare)
  • Access to novel anti-diabetic agents in resource limited settings : A brief commentary
  • 2023
  • Ingår i: World Journal of Diabetes. - : Baishideng Publishing Group Inc.. - 1948-9358. ; 14:7, s. 939-941
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
    • The prevalence of diabetes mellitus is increasing in resource limited settings. Simultaneously, there has been an increase in the number of novel therapies for the management of diabetes mellitus. However, use of novel antidiabetic therapies is limited because of major market access challenges in resource limited settings. Niching products to those patients with the highest absolute risk for major adverse cardiovascular outcomes, and thus most likely to benefit from the therapy, are less likely to have negative budget impact for funders. To improve access, and reduce morbidity and mortality, requires alignment amongst key stakeholders including patient advocacy groups, health care professional councils, national departments of health, the pharmaceutical industry, treasury and finance departments.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-9 av 9

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy